Drug Summary & History
Chloramine-T INAD 9321

Bacterial gill disease (BGD), caused by Flavobacteria branchiophilum and other external flavobacteria, is a potentially acute disease of intensively cultured fish, particularly young salmonids. If BGD is not diagnosed and treated early, epizootics may occur within a 24-h period. External flavobacteria, caused by F. columnare, F. psychrophilum, and other closely related yellow-pigmented gliding bacteria are often collectively termed “external flavobacteriosis” and are chronic to acute diseases that have been reported in many species of cultured cold-, cool-, and warmwater fish. External flavobacteriosis and BGD may occur at a wide range of water temperatures.

Historically, chloramine-T (CHL-T) has been widely used to successfully control mortality in fishes diagnosed with BGD and external flavobacteriosis. The primary goal of field studies conducted under INAD #9321 is to generate additional data to help demonstrate the efficacy of CHL-T to control mortality in a variety of fishes diagnosed with BGD or external flavobacteriosis. Under this INAD, Axcentive SARL/International Specialty Chemicals, Inc. (Tarrytown, NY) and B. L. Mitchell, Inc. (Greenville, MS) are the listed suppliers of CHL-T to all Investigators. Once approved by FDA, Chloramine-T will no longer be available under an INAD; the only legal source will be the sponsor of the approved product.

The standard treatment regimen for the control of mortality caused by BGD or external flavobacteriosis is a 1-h static-bath or flow-through CHL-T treatment. Chloramine-T may be administered at 10, 15, or 20 mg/L chloramine-T, and fish may be treated 1 - 3 times on alternate or consecutive days. For more details about the various treatment options available under INAD #9321, refer to the protocol. Regardless of the treatment option used, fish may be slaughtered for harvest or stocked immediately after treatment.